Eli Lilly and Company
Eli Lilly and Company, commonly referred to as Lilly, is a global leader in the pharmaceutical industry, headquartered in the United Kingdom. Founded in 1876, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative solutions in diabetes, oncology, immunology, and neuroscience. Lilly is renowned for its pioneering products, such as insulin therapies and cancer treatments, which are distinguished by their commitment to research and development. The company has achieved significant milestones, including the introduction of groundbreaking medications that have transformed patient care. With a robust market position, Eli Lilly continues to be recognised for its contributions to healthcare, consistently ranking among the top pharmaceutical companies worldwide.
DitchCarbon Score
How does Eli Lilly and Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eli Lilly and Company's score of 38 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eli Lilly and Company's reported carbon emissions
In 2023, Eli Lilly and Company reported total carbon emissions of approximately 5,182,000 kg CO2e across all scopes. This includes 182,000 kg CO2e from Scope 1, 345,000 kg CO2e from Scope 2, and a significant 5,139,500 kg CO2e from Scope 3 emissions. The Scope 3 emissions are primarily driven by purchased goods and services, which accounted for about 3,098,800 kg CO2e. Eli Lilly has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The company has consistently reported emissions across all three scopes, indicating a comprehensive approach to tracking its environmental impact. Historically, Eli Lilly's emissions have shown fluctuations, with Scope 1 emissions decreasing from 527,000,000 kg CO2e in 2007 to 182,000 kg CO2e in 2023. This reflects a broader trend of increasing awareness and action towards sustainability within the pharmaceutical industry. Overall, while Eli Lilly has made strides in emissions reporting and management, further details on specific reduction initiatives or targets would enhance understanding of their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 527,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,310,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 14,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eli Lilly and Company is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
